| DB ID | MyCo_1230 |
| Title | COVID-19 and candiduria: an investigation of the risk factors and immunological aspects |
| Year | 2023 |
| PMID | 37405625 |
| Fungal Diseases involved | Candidemia |
| Associated Medical Condition | Covid-19 |
| Genus | Candida |
| Species | tropicalis |
| Organism | Candida tropicalis |
| Ethical Statement | This study was approved by the National Ethics Committee (Comissão Nacional de Ética em Pesquisa- CONEP) and the hospital's Ethics Committee (CAAE: 30627320.6.0000.0008). |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | IL-2 |
| Biomarker Full Name | Interleukin-2 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Brazil |
| Cohort | Between May and November 2020, we enrolled patients with COVID-19 and candiduria coinfection (n=18) and patients with COVID-19 alone as a control group (n=31), admit- ted in the ICU of the Hospital Eduardo de Menezes, Belo Horizonte, Brazil. The control group was determined by randomly selecting patients with a diagnosis of COVID-19, which had no reported candidemia/candiduria during their ICU stay. |
| Cohort No. | 18 Patients and 31 Controls |
| Age Group | None |
| P Value | p=0.0241 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | The severe tissue damage, the immunologic derangement resulting from SARS-CoV-2 infection, and the invasive pro- cedures in the severe cases frequently predispose to secondary fungal infections. Previous studies have demon- strated a higher number of cases of COVID-19-associated candidiasis (CAC), aspergillosis (CAPA), mucormycosis (CAM), and histoplasmosis in the different countries. Candida species are major constituents of the human mycobiome and the leading cause of invasive fungal infec- tions. Studies from Spain, India, Italy, UK, and China reported occurrence rates of CAC of 0.7% (7/989), 2.5% (15/ 596), 8% (3/43), 12.6% (17/135), and 23.5% (4/17), respectively. Overall, due to neglected approach towards fungal infections, morbidity and mortality has been showed to worsen during the COVID-19 pandemic. For example, a recent systematic review showed that CAC doubled the mortality of critically ill COVID-19 patients. In addition, a previous study from our group revealed that hospitalized patients with severe COVID-19 and can- diduria have a 5-times higher risk of death when compared to patients without the coinfections. |
| Technique | Assay |
| Analysis Method | Bio-Plex Pro™ Human Cytokine 27-plex Assay (Bio-Rad, Hercules – CA, USA) |
| ELISA kits | Bio-Plex Pro™ Human Cytokine 27-plex Assay (Bio-Rad, Hercules – CA, USA) |
| Assay Data | None |
| Validation Techniques used | Bio-Plex Pro™ Human Cytokine 27-plex Assay |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
